Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
63 results about "Aryl hydrocarbon receptor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The aryl hydrocarbon receptor (AhR or AHR or ahr or ahR) is a protein that in humans is encoded by the AHR gene. The aryl hydrocarbon receptor is a transcription factor that regulates gene expression. It was originally thought to function primarily as a sensor of xenobiotic chemicals and also as the regulator of enzymes such as cytochrome P450s that metabolize these chemicals. The most notable of these xenobiotic chemicals are aromatic (aryl) hydrocarbons from which the receptor derives its name.
Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
The present invention relates to methods, kits and compositions for expansion of hematopoietic stem / progenitor cells and providing hematopoietic function to human patients in need thereof. In one aspect, it relates to kits and compositions comprising a Notch agonist and an aryl hydrocarbon receptor antagonist. Also provided herein are methods for expanding the hematopoietic stem / progenitor cells using kits and compositions comprising a Notch agonist and an aryl hydrocarbon receptor antagonist. The hematopoietic stem / progenitor cells expanded using the disclosed kits, compositions and methods include human umbilical cord blood stem / progenitor cells, placental cord blood stem / progenitor cells and peripheral blood stem cells. The present invention also relates to administering hematopoietic stem / progenitor cells expanded using a combination of a Notch agonist and an aryl hydrocarbon receptor antagonist to a patient for short-term and / or long-term in vivo repopulation benefits.
Owner:NOVARTIS AG +1
Indirubin-Type Compounds, Compositions, and Methods for Their Use
Compounds and compositions including 6-bromo-indirubin, 5-amino-indirubin and N-methyl-indirubins and related indirubin derivatives are provided that are useful as selective modulators of glycogen synthase kinase-3, cyclin-dependent protein kinases or aryl hydrocarbon receptors. Methods of inhibiting or modulating cell growth or cell cycling are provided using the compounds of the invention. In other aspects, compounds and methods for the treatment of protozoan-mediated diseases, Alzheimer's disease and diabetes are provided.
Owner:MEIJER LAURENT +3
Methods to modulate acute myeloid leukemia stem/progenitor cell expansion and/or differentiation
Novel methods for modulating acute myeloid leukemia stem / progenitor cell expansion and / or differentiation are disclosed. These methods are based on the use of aryl hydrocarbon receptor (AhR) modulators and / or compounds of formula I or IIScreening assays to identify compounds that may be useful for inhibiting and / or eliminating AML initiating cells using AhR modulators and / or the compounds of formula I or II are also disclosed. The use of pharmaceutically acceptable agonists of the AhR for preventing or inhibiting minimal residual disease (MRD) in an AML patient is also disclosed.
Owner:UNIV DE MONTREAL +1
Ah receptor antagonists
The invention relates to the field of aryl hydrocarbon receptor (Ah receptor; AhR) antagonists and their uses.
Owner:SYMRISE GMBH & CO KG
Methods of Culturing and Expanding Mesenchymal Stem Cells and Isolated Cell Populations Generated Thereby
A method of culturing mesenchymal stem cells (MSCs) is provided. The method comprising culturing a population of the MSCs in a medium comprising an aryl hydrocarbon receptor antagonist, thereby culturing MSCs.
Owner:GAMIDA CELL
Production of red blood cells and platelets from stem cells
This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (MEP), comprising differentiating a stem cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) agonist. In some embodiments the stem cell is a pluripotent stem cell. In some embodiments the MEP co-expresses CD41 and CD235. In some embodiments the number of MEPs produced in the culture increases exponentially. Methods of making a red blood cell (RBC) by culturing a MEP in the presence of an AhR agonist are also provided. Methods of making a megakaryocyte and / or a platelet, comprising culturing a MEP in the presence of an AhR modulator are also provided. In some embodiments the AhR modulator is an AhR antagonist. This disclosure also provides compositions comprising at least 1 million MEPs per ml and compositions in which at least 50% of the cells are MEPs.
Owner:TRUSTEES OF BOSTON UNIV +1
Application of evodiamine in preparing medicine for inhibiting aryl hydrocarbon receptor
The invention relates to application of evodiamine in preparing a medicine for inhibiting an aryl hydrocarbon receptor. The medicine for inhibiting the aryl hydrocarbon receptor has the anti-tumor and immunoregulation effects by inhibiting the aryl hydrocarbon receptor, wherein the tumors are breast cancer, endometrial cancer, prostate cancer, lung cancer, gastric cancer, liver cancer, colon cancer and the like; and the immunoregulation is performed aiming at various inflammatory related diseases, such as sepsis, sepsis shock, rheumatic arthritis, rheumatoid arthritis, asthma, acute and chronic glomerulonephritis, and systemic lupus erythematosus. In the application, the evodiamine is an alkaloid component in a traditional Chinese medicine, namely medicinal evodia fruit, has the molecular formula of C19H17NO3 and the molecular weight of 303.4Da, is insoluble, can be dissolved in organic solvents such as dimethyl sulfoxide, ethanol, diethyl ether and chloroform, and has the melting point of 278 to 279 DEG C.
Owner:THE THIRD AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIV OF PLA
Production of red blood cells and platelets from stem cells
This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (MEP), comprising differentiating a stem cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) agonist. In some embodiments the stem cell is a pluripotent stem cell. In some embodiments the MEP co-expresses CD41 and CD235. In some embodiments the number of MEPs produced in the culture increases exponentially. Methods of making a red blood cell (RBC) by culturing a MEP in the presence of an AhR agonist are also provided. Methods of making a megakaryocyte and / or a platelet, comprising culturing a MEP in the presence of an AhR modulator are also provided. In some embodiments the AhR modulator is an AhR antagonist. This disclosure also provides compositions comprising at least 1 million MEPs per ml and compositions in which at least 50% of the cells are MEPs.
Owner:TRUSTEES OF BOSTON UNIV +1
Application of AhR (Aryl hydrocarbon receptor) protein inhibitor to preparation of antiviral drugs
The invention belongs to the technical field of biological medicine, and relates to antiviral drugs, in particular to application of a host AhR (Aryl hydrocarbon receptor) protein inhibitor baicalin compound or a composition of the baicalin compound and other antiviral drugs to preparation of drugs for clinical treatment of various virus infective diseases. The baicalin compound has the functions of interfering with a host AhR protein signal channel, blocking virus replication and further antagonizing the activity of various viruses. The baicalin compound can be made into a pharmaceutical composition with other anti-virus drugs to be used for treating diseases like hepatitis B virus, influenza virus, herpes virus and syncytial virus.
Owner:FUDAN UNIV
ARYL HYDROCARBON RECEPTOR (AhR) MODIFIERS AS NOVEL CANCER THERAPEUTICS
Owner:TRUSTEES OF BOSTON UNIV +2
Diagnostics and therapeutics for diseases associated with aryl hydrocarbon receptor (ahr)
The invention provides a human AHR which is associated with the disorders of the peripheral and central nervous system, cardiovascular diseases, hematological diseases, cancer, inflammation, respiratory diseases, urological diseases and gastroenterological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders of the peripheral and central nervous system, cardiovascular diseases, hematological diseases, cancer, inflammation, respiratory diseases, urological diseases and gastroenterological diseases. The invention also features compounds which bind to and / or activate or inhibit the activity of AHR as well as pharmaceutical compositions comprising such compounds.
Owner:BAYER HEALTHCARE AG
Carrier suitable for cell transformation, recombinant cell and application thereof
InactiveCN102851312AMicrobiological testing/measurementChemiluminescene/bioluminescenceDioxin CompoundResponse element
The invention provides a carrier suitable for cell transformation, a recombinant cell and an application thereof, wherein a group of carriers suitable for cell transformation comprise a first carrier and a second carrier. The first carrier comprises a first nucleic acid sequence; the first nucleic acid sequence comprises a sequence coding report protein; and the report protein has detectable activity; the first nucleic acid sequence also comprises a dioxin response region which comprises a dioxin response element; and the dioxin response region is operably connected with the first nucleic acid sequence. The second carrier comprises a second nucleic acid sequence, and the second nucleic acid sequence comprises a sequence coding an aromatic hydrocarbon receptor. The carrier suitable for cell transformation and the recombinant cell of the invention are applicable to detection of dioxin compounds.
Owner:SHENZHEN HUADA GENE INST +1
ARYL HYDROCARBON RECEPTOR (AhR) MODIFIERS AS NOVEL CANCER THERAPEUTICS
Provided herein are novel agents that modulate AhR activity for use in therapeutic compositions and methods thereof for inhibiting cancer cell proliferation and tumor cell invasion and metastasis. The agents comprise AhR inhibitors or non-constitutive AhR agonists of Formula (I) and (II) for the inhibition of cancer cell growth and parameters that characterize tumor metastasis, such as tumor cell invasiveness.
Owner:NORTHEASTERN UNIV +2
Method and system of detecting dioxin-like compounds
ActiveCN104395753ABiological material analysisMaterial analysis by optical meansEnergy transferResonance
Owner:E BIO ENTERPRISE LTD
Cells and methods for estimation of effects on neurological dysfunction
The invention provides neuron-derived cells obtained by transfecting a receptor-expressing nucleic acid having an aryl hydrocarbon receptor gene, wherein outgrowth of neurites is not observed without adding a substance for the aryl hydrocarbon receptor, and outgrowth of neurites is observed by adding the substance for the aryl hydrocarbon receptor. The invention also provides a method for determining the presence of neurotoxicity of a test substance, a method for acquiring a marker for determining the presence of neurotoxicity of the test substance, a method for acquiring a marker for neurological dysfunction, and a method for determining the effect of the test substance on neurological dysfunction using such cells.
Owner:KK TOSHIBA
Method for Producing Highly Functional Platelets
ActiveUS20190048317A1Efficient productionFunctionalOrganic active ingredientsMammal material medical ingredientsKinaseCoiled coil
The present invention provides a highly functional platelet production promoting agent which comprises one or a plurality of aryl hydrocarbon receptor (AhR) antagonists and one or a plurality of Rho-associated coiled-coil forming kinase (ROCK) inhibitors.
Owner:KYOTO UNIV +1
Heterocyclic compound
PendingCN112654627AExcellent aryl hydrocarbon receptor antagonist activityPromote productionOrganic chemistryBlood disorderArylReceptor antagonist activity
Owner:OTSUKA PHARM CO LTD
Methods Of Inhibiting the Activity of Hsp90 and/or Aryl Hydrocarbon Receptor
The present invention relates to a method of screening compounds for binding to hsp90 by exposing a compound to hsp90 or a polypeptide fragment thereof containing amino acid residues 538-728 of the full length protein and determining whether the compound binds to hsp90 of the polypeptide fragment thereof. Also disclosed is a method of screening compounds for inhibition of hsp90 activity. The present invention further relates to a method of screening compounds as a cancer therapeutic and a method of treating cancerous conditions. Also disclosed is a method of inhibiting transcription-inducing activity of an aryl hydrocarbon receptor in a cell and a method of modifying expression of a gene that is-activated by an aryl hydrocarbon receptor.
Owner:UNIVERSITY OF ROCHESTER
Diagnostic and immunotherapy compositions and methods for disease states mediated by inhibitor-resistant cd8 t-cells
Owner:JOHNSON RAYMOND M
Humanized recombinant vector and cell for dioxin-type substance biological detection
InactiveCN105886532AResponsiveMicrobiological testing/measurementNucleic acid vectorLuciferaseBiology
The invention relates to a recombinant vector and a recombinant cell, in particular to a humanized recombinant vector and recombinant cell for detecting aromatic hydrocarbon receptor ligands (such as dioxin-type substances). The invention also relates to a purpose of the recombinant vector and cell in the aspects of biological detection of aromatic hydrocarbon receptor ligands (such as dioxin-type substances). The DRE-sequence-containing human CYP1A1 gene promoters or partial segments of the promoters are cloned to a basic genetic vector with a luciferase recording gene, the obtained recombinant vector and cell have good response on the dioxin; the lowest detection limit can reach 0.3pM; the humanized recombinant vector and cell are particularly suitable for elevating the influence of the aromatic hydrocarbon receptor ligands (such as dioxin-type substances) on the human body health and performing relevant mechanism study.
Owner:RES CENT FOR ECO ENVIRONMENTAL SCI THE CHINESE ACAD OF SCI
Composition for preventing inflammations
ActiveUS9095604B2Safely be taken orallyEfficient processCompound screeningOrganic active ingredientsAryl hydrocarbon receptorInflammation
Owner:MEIJI CO LTD
Methods of culturing and expanding mesenchymal stem cells
A method of culturing mesenchymal stem cells (MSCs) is provided. The method comprising culturing a population of the MSCs in a medium comprising an aryl hydrocarbon receptor antagonist, thereby culturing MSCs.
Owner:GAMIDA CELL
Methods and compositions relating to hematopoietic stem cell expansion
PendingUS20190119642A1Lower Level RequirementsInhibit phosphorylationNervous disorderSkeletal disorderUbiquitin ligase complexReceptor Inhibition
Described herein are methods and compositions relating to expanding, enriching, and / or maintaining a population of hematopoietic stem cells ex vivo. In some embodiments, the methods and compositions can relate to a combination of two or more agents, e.g., an agent that increases the expression of a Notch target gene; an agent that activates a ubiquitin ligase complex comprising cereblon; a compound that inhibits BMP signaling; a modulator of histone methylation; an inhibitor of TGFβ signaling; an inhibitor of p38 signaling; an activator of canonical Wnt signaling; a modulator of histone acetylation; a compound represented by formula (1); an aryl hydrocarbon receptor inhibitor; a histone demethylase inhibitor; a TGFβ receptor inhibitor; a compound that inhibits a protein that propagates p38 signaling; a compound that inhibits a protein that promotes β-catenin degradation; a histone deacetylase inhibitor; Prostaglandin; an agonist of Notch signaling; an inhibitor of SIRT1; UM171; and / or a compound listed in Table 1.
Owner:CHILDRENS MEDICAL CENT CORP
Topical compositions and methods for treating inflammatory skin diseases
ActiveUS20210186931A1Prevent relapseReduce frequencyOrganic active ingredientsAntipyreticPalmoplantar pustulosisHidradenitis
Compositions and methods for treating skin conditions, ailments or diseases, such as autoinflammatory skin diseases such as psoriasis, dermatitis, pyoderma gangrenosum, palmoplantar pustulosis, prurigo nodularis and / or hidradenitis suppurativa, are described. The compositions comprise an agent that modulates the aryl hydrocarbon receptor, in particular an agent that agonizes the receptor. In one embodiment, the agent is indigo or a derivative of indigo, such as indirubin.
Owner:AZORA THERAPEUTICS INC
Beta-naphthoisoflavones, compositions containing, and uses of, same
The present invention provides compounds of the following structure,methods of using such compounds, and pharmaceutical compositions containing such compounds. In addition, this invention provides methods for the treatment and / or prevention of disease states mediated by Aryl Hydrocarbon receptor pathways.
Owner:THESAN PHARMA
Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
InactiveUS9834755B2Mammal material medical ingredientsBlood/immune system cellsProgenitorCord blood stem cell
Owner:NOVARTIS AG +1
Starch-indolic acid derivative, preparation method and application thereof
ActiveCN113912743AIncrease contentIncrease resistanceAntipyreticMetabolism disorderIntraperitoneal routeVenous blood
The invention provides a starch-indolic acid derivative, a preparation method and application thereof, and relates to the technical field of modified starch. According to the invention, the starch-indolic acid derivative is esterified starch generated by esterification reaction of starch and indolic acid under the action of a condensing agent and and alkali, has relatively high resistance, can resist degradation of the stomach and the small intestine, can release indolic acid beneficial to intestinal health through fermentation of intestinal flora after reaching the colon part, has obvious advantages compared with traditional administration modes such as intragastric administration, intraperitoneal injection and the like, and can obviously increase the content of indolic acid in colon and hepatic portal venous blood; and indoleic acid can activate an aromatic hydrocarbon receptor to play an immunoregulation role, and the indoleic acid and the regulation role of short-chain fatty acid released by fermentation of starch with intestinal flora are superposed, so that a product which synergistically plays the immunoregulation role through a plurality of immune system signal pathways is provided.
Owner:SHANDONG SHANWEI IMMUNOTECH CO LTD
Formulations with Anti-neoplastic activity
InactiveUS20110293537A1Easy accessExtended half-lifeBiocideHydroxy compound active ingredientsCyclodextrinPharmaceutical formulation
Pharmaceutical formulation comprising at least one aryl hydrocarbon receptor ligand and at least one cyclodextrin for the prevention and / or treatment of carcinomas, preferably squamous cell carcinomas, more preferably oral squamous cell carcinomas.
Owner:BERTA GIOVANNI NICOLAO
Polymorphic compounds and uses thereof
ActiveUS20210253579A1Prevention and reduction of risk of diseasePrevent and reduce riskAntipyreticOrganic chemistry methodsAryl hydrocarbon receptorSmall molecule
The present invention provides freebase and salt forms, and compositions and methods thereof, useful for treating various conditions in which the aryl hydrocarbon receptor (AHR) is implicated, by the administration of small molecule therapeutics which act as inhibitors of AHR.
Owner:IKENA ONCOLOGY INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com